Shunsuke Niwa

Title: Shunsuke Niwa: Innovator in Monoclonal Antibody Development

Introduction

Shunsuke Niwa is a prominent inventor based in Tokyo, Japan. He is known for his significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work has the potential to impact the diagnosis and treatment of malignant tumors.

Latest Patents

Shunsuke Niwa holds a patent for a monoclonal antibody against human GPR87. This invention provides a novel means for diagnosing or treating malignant tumors. The monoclonal antibodies can recognize human GPR87, which is expressed on cell membranes while retaining a three-dimensional structure. They can also recognize GPR87 expressed endogenously, with an epitope present in the extracellular domain of full-length human GPR87. This innovation is useful in biochemical analysis and immunohistological diagnosis of squamous cell carcinoma, and it holds potential for PET diagnosis and treatment of this type of cancer.

Career Highlights

Throughout his career, Shunsuke Niwa has worked with notable organizations, including Perseus Proteomics Inc. and the University of Tokyo. His experience in these institutions has contributed to his expertise in the field of monoclonal antibodies and cancer research.

Collaborations

Shunsuke Niwa has collaborated with esteemed colleagues such as Takao Hamakubo and Yasuhiro Mochizuki. These partnerships have furthered his research and development efforts in the biotechnology sector.

Conclusion

Shunsuke Niwa's innovative work in monoclonal antibodies represents a significant advancement in the fight against malignant tumors. His contributions to biotechnology continue to pave the way for new diagnostic and therapeutic approaches.